Trying to do better each day. Hoping for the best
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok so what's the top, I want to make sure I don't miss it
Want any teens, you better hurry!
This sounds like they could be working with other sources.
"These important events allow the Company to share ideas and build on our current collaborations for research and multi-center clinical trials."
Is that what it sez? Blocked at work
Alright by me!
I would say it's probably not happening today
That info is above my paygrade
At least someone is Busy in Africa
http://www.otcmarkets.com/news/otc-market-headline?id=898859
Cannabis Science Presents Its African Drug Development Initiative at Major U.S.-Africa Policy Conference
Building on Current Collaborations for Educational & Economic Research with Multi-Center Clinical Trials
IRVINE, CA -- (Marketwired) -- 09/27/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, presented an update to its African Drug Development Initiative at the Constituency for Africa's (CFA) Ronald H. Brown African Affairs Series in Washington, DC last week. Convened annually, the Ronald H. Brown Series is a major U.S.-Africa Policy Forum, and is attended by stakeholders from government, private sector, civil society, academia, and the media from the U.S., Africa, and the African Diaspora.
"CFA's Ronald H. Brown African Affairs Series is an important annual event for Cannabis Science. In addition to this series, the Company presented at the Global Health Catalyst Summit at Harvard Medical School in April of this year, and we plan to present at the African Organization for Research and Training in Cancer (AORTIC) Conference in Rwanda in November," stated Dr. Herman. "These important events allow the Company to share ideas and build on our current collaborations for research and multi-center clinical trials."
During the Healthcare roundtable on Strengthening Healthcare Infrastructure in Africa, Cannabis Science's President and CEO, Mr. Raymond Dabney, and the Company's Chief Medical Officer (CMO), Dr. Allen Herman, presented an update on Cannabis Science's African Drug Development Initiative which includes educational and job creation programs.
The theme of the Healthcare Roundtable was Reversing Africa's Brain Drain: The Role of the African Diaspora in Strengthening the Healthcare Infrastructure of Africa, and the session explored strategies to invest in and develop Africa's health workers, healthcare and social services infrastructure, logistics, surveillance and health information systems, healthcare governance, and drug supply systems. The roundtable was moderated by the Honorable Donna Christensen, former Member of the U.S. House of Representatives, and former Chair of the Congressional Black Caucus Health Braintrust; and Ambassador Bonnie Jenkins, Joint Visiting Fellow at the University of Pennsylvania Perry World House and Brookings Institution. Distinguished speakers included the Honorable Dr. Arikana Chihombori, the African Union's Ambassador to the U.S.; Dr. John Nkengasong, Director of the Africa Centers for Disease Control and Prevention; Professor Akin Abayomi, Principal Investigator for the Global Emerging Pathogens Treatment Consortium (GET Africa); and Dr. Wilfred Ngwa, Global Health Catalyst Director at the Dana-Farber/Harvard Cancer Center.
"This is the third year that Cannabis Science has presented at CFA's Ronald H. Brown African Affairs Series. Each year, we have been able to create new opportunities for our Company through active engagement with thought-leaders in our industry, as well as through the formation of new collaborations with individuals and institutions," stated Mr. Dabney. "As a result of this year's conference, we expect to accelerate our activities in a number of African countries."
In addition to attending the AORTIC Conference in Rwanda, the Company will sponsor a special session on the Use of Cannabinoids to Treat Cancers. This session will focus on the potential use of cannabinoids in treating cancers and other indications, helping to close the global pain divide, and on establishing partnerships with key stakeholders worldwide to accelerate research, and possible clinical translation of cannabinoid-based medicines. Information on the AORTIC Conference can be viewed at http://aorticconference.org/.
Through Cannabis Science's collaborations, the company is executing its research and development plan and initial results were recently published in the cancer research journal Frontiers in Oncology. The article can be viewed at http://journal.frontiersin.org/article/10.3389/fonc.2017.00208/full.
This publication titled, "Nanoparticle drones to target lung cancer with radiosensitizers and cannabinoids," addresses drug delivery, and highlights an innovative strategy to deliver cannabinoids directly to cancer cells with minimal toxicities or side effects that have so far hampered clinical translation efforts.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
That's it! Keeping chipping away 2 mil at a time
I tend to agree. Never really ever knew what side of the fence he is on. He may be right about the license. Sounds logical. Probably all that is left is just making it official.
Somebody needs to step up with 17k and finish off those 8's if they are actually for sale.
Shouldn't the "D" stand for deposits
Just answer the question truthfully, that wasn't an answer. If you have all the answers for TXTM. You should be able to answer that too. Thanks in advance
If what U say is true then why in the world would you spend endless hours posting about TXTM, wasting precious time that U could be enjoying life? I looked at your library of posts and looks like 99% of them are on this board.
WE? I thought U were just here to post negativity! Didn't know U were a shareholder! GOOD WE can go up now!
This sure sounds BULLISH,
Dept. of Health (DoH) Deputy Director Law Enforcement, Griffith Molewa, said they would approve regulations in the next few weeks. The MCC indicated that licenses would be issued thereafter.
YES! YES! Protext Pharma Announces South Africa's Reclassification of Cannabis as a Schedule 4 Substance
http://www.otcmarkets.com/news/otc-market-headline?id=894230
Company Provides Update on its Cannabis License Application
BOCA RATON, FL -- (Marketwired) -- 09/20/17 -- Protext Pharma, Inc. (PINKSHEETS: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today announced that the government of South Africa published recommended amendments to the Medical Innovation Bill that would change the status of cannabis products that do not have psychoactive properties from a Schedule 7 prohibited substance to a Schedule 4 substance. Schedule 4 drugs, which include antibiotics and corticosteroids, may be given verbally to the pharmacist by the doctor, although such instruction must be followed up by a written prescription within 7 days. Under the proposed guidelines, Cannabis sold "on the street" will remain a Schedule 7 substance and be prohibited. Protext Pharma anticipates that its Phytofare® Cannabinoid extract will be non-psychoactive and thus fall under the Schedule 4 classification.
This announcement follows the Medicines Control Council's (MCC) proposed guidelines for growing cannabis for medicinal purposes, which was published for comment in March 2017. In last week's Medical Innovation Bill (Cannabis guidelines) briefing of the portfolio committee on health, Dept. of Health (DoH) Deputy Director Law Enforcement, Griffith Molewa, said they would approve regulations in the next few weeks. The MCC indicated that licenses would be issued thereafter.
Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, "From where we sit, the cannabis reclassification is a very positive development and it's encouraging to see South Africa take a leading role in recognizing the potential medical benefits of cannabis and pave the way for new research. South Africa is one of only a few countries around the world to have achieved governmental support for the legalization of cannabis for medical use. There is a growing body of evidence indicating cannabis can help regulate the endocannabinoid system, which explains its perceived benefits for a host of ailments especially inflammation, depression, post-traumatic stress, muscle spasticity, chronic pain, and other neural disorders. The cannabis business is a large and emerging market anticipated to grow to $55.8 billion by 2025. Our segment of this market, cannabis based medicines, is at the cusp of what could be a new industry for decades to come."
With regards to the much-anticipated license which would allow the company to proceed with developing a cannabis medicines platform in South Africa, Mr. Duffield stated, "Despite the licensing process taking longer than anticipated, we remain confident that the issuance of a cannabis license allowing the Company to grow cannabis for the purpose of research and producing cannabis based medicines is still on track. We believe we're uniquely positioned to be granted this license having developed an expertise in the extraction of phytonutrients from live plants, as well as having a home base and corporate presence in South Africa for some years. On Tuesday of this week, we were notified by the DoH that our application has now moved on to the Narcotic Desk of SAPS (South African Police Service) for police clearance of all applicants to check for suitability in handling cannabis, as per the MCC guidelines published March 2017. The Company is in regular communication with senior government officials at the Ministry of Health and we expect to have the license issued once the final regulations are ratified, which, according to statements from government, should be very soon."
Once the license is issued, the company intends to use a 10,000 square foot facility in the Mpumalanga province where plants will be grown, cloned and cultivated to ensure a consistent chemical profile. The facility will incorporate an on-site laboratory which will be designed and engineered to process live plant material and after separation and recovery of the oil-phase as a separate income stream, the final stage will be specific to the production of the Phytofare® complex containing cannabinoids, cannabinoid acids, terpenes, limonene and polyphenols. The resulting complex will be subjected to product profiling, analysis and bioavailability in order to determine efficacy and dosage. The Company will use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plants. The Company's investigations will be designed to show that the extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.
Doesn't have to. It's the Gospel! lol
https://www.walmart.com/search/?query=disposable%20diaper&cat_id=0
This search for disposable diaper shows 3 Mothers Touch on the 1st page. I guess Walmart.com is wrong, messed up, got a virus or a conspiracy going on huh?
Over 400 subscribers added in 3 weeks = 400 x $39.95 = $15,980 x 12 months = $191,760 a year, not too bad for 3 weeks work
I wish you were right but not enough meat to give this what it needs. We need something undeniable or I am afraid it just gave it a nudge to keep it off the bottom a little while longer. I hope it proves me wrong. Just saw the 8mil at 7 go through.
Don't mean to sound negative but push, push, push for 3 days just to get it up to 1 and it could have closed at 6 or 7 just as easily as it did at 9 today
Yeah but let's see if it will ever hold any traction for more than just a brief few days
Guess I should have said 6
Looks like it will be lucky not to drop to 7
Protext Pharma to Conduct Clinical Trial to Determine Therapeutic Dosage Levels for Treating Diabetes
http://www.otcmarkets.com/news/otc-market-headline?id=888306
Not TXTM but Africa & Cannabis
http://www.otcmarkets.com/stock/CBIS/news
Cannabis Science Announces Participation in Major U.S.-Africa Policy Forum in Washington, DC
IRVINE, CA -- (Marketwired) -- 09/11/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, announces that its senior executives will participate in the Constituency for Africa's (CFA) 2017 Ronald H. Brown African Affairs Series. The Series will be held September 18th-22nd in Washington, DC.
For over 26 years, CFA has established itself as one of the leading, non-partisan organizations focused on educating and mobilizing the American public and the African Diaspora in the U.S. on U.S.-Africa policy. As a result, CFA has helped to increase the level of cooperation and coordination among a broad-based coalition of individuals and organizations committed to the progress, development, and empowerment of Africa and African people worldwide.
The highlight of CFA's annual initiatives is the Ronald H. Brown African Affairs Series. The theme of this year's series is Mobilizing the Diaspora in Support of the U.S.-Africa Agenda, and the series is being organized by CFA in cooperation with the African Union Mission to the United States. The purpose of the 2017 Series is to bring together stakeholders from the U.S., Africa, and the African Diaspora to assess the U.S. Administration's Africa policy, and to identify challenges and opportunities in a number of key areas, including African healthcare infrastructure. The expected outcomes of the Series will include policy recommendations for the U.S. Administration and the African Union.
Mr. Raymond C. Dabney, Cannabis Science's President, CEO, Co-founder, and Director, and Dr. Allen Herman, CBIS' Chief Medical Officer, will deliver remarks at CFA's African Healthcare Infrastructure Roundtable on Tuesday, September 19th, and participate in a bi-partisan, senior-level U.S.-Africa Policy Forum on Thursday, September 21st. "I look forward to Cannabis Science's participation in this year's Ronald H. Brown African Affairs Series. This Series provides our company with the opportunity to engage with key U.S. and African stakeholders in government, private sector, civil society, and academia. These potential partnerships will enable Cannabis Science to accelerate our African drug-development initiative, as well as to build on our current collaborations for research and multi-center clinical trials," stated Mr. Dabney.
The theme of CFA's African Healthcare Infrastructure Roundtable is Reversing Africa's Brain Drain: The Role of the African Diaspora in Strengthening the Healthcare Infrastructure of Africa. This roundtable will explore strategies that invest in Africa's health workers, healthcare and social services infrastructure, logistics, surveillance and health information systems, healthcare governance, and drug supply systems. Confirmed speakers will include H.E. Arikana Chihombori, the African Union's Permanent Representative to the United States; Dr. Roscoe M. Moore, Jr., former Assistant United States Surgeon General and Rear Admiral, United States Public Health Service (Retired), and Interim Chairman of CFA's Board of Directors; Dr. John Nkengasong, Director of the Africa Centers for Disease Control and Prevention; and Professor Akin Abayomi, Principal Investigator (Academic) of the Global Emerging Pathogens Treatment Consortium (GET Africa), and Chief Pathologist and Head of the Division of Hematology at the University of Stellenbosch (South Africa).
Mr. Dabney will participate in a panel discussion on Investing in African Healthcare Infrastructure, and his remarks will focus on exploring drug development opportunities in Africa. As part of his remarks, Mr. Dabney will provide an update to stakeholders on specific activities the company is implementing that will positively impact the communities where the company operates, including cities throughout Africa. CBIS' comprehensive approach leverages the company's core competencies to contribute to overall economic development through education and training, food security and agriculture, technology and communications, and the implementation of public policies that create the enabling environment for the aforementioned.
For his remarks, Dr. Herman will provide an update on the operational strategy he developed for CFA's African Healthcare Infrastructure Committee, a network of Africa-focused healthcare experts launched during CFA's Ronald H. Brown Series in 2015.
CFA's U.S.-Africa Policy Forum will be the highlight of the 2017 Ronald H. Brown African Affairs Series. Policy Forum participants will discuss, debate, and ultimately agree on a strategy to improve U.S.-Africa cooperation in a number of key policy issues, including on strengthening Africa's healthcare infrastructure. The Policy Forum will be moderated by Ambassador Reuben E. Brigety, Dean of the Elliott School of International Affairs at The George Washington University, and former U.S. Representative to the African Union.
For more information on CFA's Ronald H. Brown African Affairs Series, please visit www.ronaldbrownseries.org.
Mr. Dabney is a Co-chair of the 2017 Ronald H. Brown African Affairs Series, and a member of the CFA Board of Directors. Cannabis Science is an official sponsor of this year's Series.
Sorry, looked at the number wrong. Still needs another 3.5 mil. Guess I need to clean my glasses.
Already matched the 100d avg volume
Sounds good but been sitting on the tarmac so long, I hope we don't run out of fuel before takeoff
That's just .14 per share if it happened at today's closing price. A long ways from $5
Sounding like another month of trading before the split
Maybe all today, but what about tomorrow?
2 trades after hours, 1 @ 6mil the other over 20mil
Theoretically could there be a breakout without charts? If charts don't matter then lower highs and lows and higher highs and lows and support and resistance would mean nothing, I guess.
I agree. Closed above resistance
The I Gloom scam has been exposed again. How could a South African diaper scam be selling at Walmart.com? Must not be a scam!
Here's the proof
$39.99
Sold & shipped by Walmart
Free shipping
Arrives within 3-5 days
Faster shipping options available at checkout
Shipping options
Choose a storeto see pickup availability
Quantity:
1
Add to Cart
Add to List
Add to Registry
Introducing Free 2-Day Shipping. No membership fee! Restrictions apply. Shop now.
I wonder how I Gloom will twist this as nothing. It says plain "sold and shipped by Walmart."
New symbol is now showing up on my ST chart screen